Allogene Therapeutics and Foresight Diagnostics Announce Par

Partnership Will Utilize Foresight’s Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene’s ALPHA3 Trial SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 -- Allogene...

Related Keywords

Zachary Roberts , Sara Head , David Chang , Axicabtagene Ciloleucel , Christine Cassiano , Leslie Bryant , Polatuzumab Vedotin , Madeleine Goldstein , Jake Chabon , Twitter , Nasdaq , Linkedin , Allogene Therapeutics Inc , Co Ting Keh , Technology To Identify Patients For Enrollment , Corporate Affairs Brand Strategy , Research Development , Drug Administration , Partnership Will Utilize Foresight , Identify Patients , Foresight Diagnostics , Chief Executive Officer , Executive Vice President , Chief Medical Officer , About Allogene , South San Francisco , Cemacabtagene Ansegedleucel , Previously Known , Regenerative Medicine Advanced Therapy , Forward Looking Statements , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Allogene Therapeutics , Investor Contact , Chief Corporate Affairs , Brand Strategy , Allogene Media Contacts , Previously Untreated Diffuse Largeb Cell , Term Follow Up , Acute Lymphoblastic , Largeb Cell , Markets ,